# Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

> **NCT06363370** · PHASE3 · RECRUITING · sponsor: **Kexing Biopharm Co., Ltd.** · enrollment: 322 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** Human interferon α1b Inhalation Solution
- **DRUG:** Inhalation Solution Placebo

## Key facts

- **NCT ID:** NCT06363370
- **Lead sponsor:** Kexing Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 322 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363370, "Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06363370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*